Abstract
Question Does neurodegenerative disease underlie the increased rate of dementia observed in older people with schizophrenia? Several studies have reported a higher prevalence of dementia in people with schizophrenia compared to the general population. This may reflect higher risk of developing neurodegenerative diseases such as vascular dementia or Alzheimer’s disease (AD). Alternatively, this may reflect nonpathological, age-related cognitive decline in a population with low cognitive reserve. We reviewed the literature on neurodegeneration markers in older people with schizophrenia and dementia or cognitive impairment to establish whether neurodegenerative disease underlies the increased rate of dementia observed.
Study Selection and Analysis We reviewed papers that compared post-mortem findings, hippocampal volume, or CSF markers of AD, in schizophrenia patients with evidence of cognitive impairment (age ≥45 years) with controls. Most studies investigated AD neuropathology. We subsequently performed a meta-analysis of post-mortem studies that compared amyloid-β plaques (APs) or neurofibrillary tangles (NFTs) in cognitively impaired schizophrenia patients to either controls or an AD group.
Findings No studies found significant increase of amyloid-β plaques (APs) or neurofibrillary tangles (NFTs) in cognitively impaired schizophrenia patients compared to controls. All postmortem studies that compared APs or NFTs in schizophrenia patients to an AD group found significantly more APs or NFTs in AD. No studies found significant differences in CSF total tau or phosphorylated tau between schizophrenia patients and controls. Two studies found significantly decreased CSF Aβ42 in schizophrenia compared to patients. Findings for hippocampal volume were mixed.
Conclusions Studies have not found higher rates of AD-related pathology in cognitively impaired schizophrenia individuals compared to controls. Higher rates of dementia identified in population studies may reflect lack of specificity in clinical diagnostic tools used to diagnose dementia.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
RH is supported by University College London Hospitals National Institute for Health Research (NIHR) Biomedical Research Centre. KL is funded by the UK Medical Research Council (MR/S021418/1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
